{"id":21391,"date":"2016-05-18T11:44:09","date_gmt":"2016-05-18T10:44:09","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=21391"},"modified":"2016-05-18T11:44:09","modified_gmt":"2016-05-18T10:44:09","slug":"els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/","title":{"rendered":"Los biosimilares llegan a la farmacia, \u00bfqu\u00e9 debemos saber?"},"content":{"rendered":"<p><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-1.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-21402 alignright\" alt=\"biosimilars-COFB-mar\u00e7-2016 (1)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-1.jpg\" width=\"298\" height=\"172\" \/><\/a>A finales de 2015 se comercializ\u00f3 en Espa\u00f1a la primera insulina biosimilar de dispensaci\u00f3n en la farmacia comunitaria, la insulina glargina Abasaglar, nombre comercial de la nueva opci\u00f3n de tratamiento para los pacientes con diabetes tipo 1 y 2. Fabricada por los laboratorios Lilly y Boehringer Ingelheim , ha sido lanzada al mercado espa\u00f1ol como un biosimilar de la insulina Lantus del laboratorio Sanofi. Se trata de la primera insulina basal biosimilar del continente europeo.<\/p>\n<figure id=\"attachment_21406\" aria-describedby=\"caption-attachment-21406\" style=\"width: 227px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-5.jpg\"><img decoding=\"async\" class=\"wp-image-21406\" alt=\"biosimilars-COFB-mar\u00e7-2016 (5)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-5.jpg\" width=\"227\" height=\"340\" \/><\/a><figcaption id=\"caption-attachment-21406\" class=\"wp-caption-text\">Fernando de Mora (UAB)<\/figcaption><\/figure>\n<figure id=\"attachment_21403\" aria-describedby=\"caption-attachment-21403\" style=\"width: 357px\" class=\"wp-caption alignright\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-2.jpg\"><img decoding=\"async\" class=\"wp-image-21403\" alt=\"biosimilars-COFB-mar\u00e7-2016 (2)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-2.jpg\" width=\"357\" height=\"238\" \/><\/a><figcaption id=\"caption-attachment-21403\" class=\"wp-caption-text\">Xavier Cos (CAP Sant Mart\u00ed de Proven\u00e7als)<\/figcaption><\/figure>\n<p>Ante la llegada de este nuevo f\u00e1rmaco, el COFB acogi\u00f3 el 31 de marzo una conferencia para informar a los farmac\u00e9uticos sobre las novedades que implica la llegada de medicamentos biosimilares a la farmacia. <b>Fernando de Mora<\/b>, director del Departamento de Farmacolog\u00eda, de Terap\u00e9utica y de Toxicolog\u00eda de la Facultad de Medicina de la Universidad Aut\u00f3noma de Barcelona, junto con <b>Xavier Cos<\/b>, m\u00e9dico de familia, director del CAP Sant Mart\u00ed de Proven\u00e7als (ICS) y Vice Chairman Primary Care Diabetes Europe, fueron los docentes responsables de la formaci\u00f3n.<\/p>\n<div class=\"box note\"><strong>Def. Biosimilares.\u00a0<\/strong>Se definen como aquellos productos medicinales de origen biotecnol\u00f3gico similares a otros f\u00e1rmacos biol\u00f3gicos innovadores, cuya patente ha expirado, producidos por un fabricante distinto, en nuevas l\u00edneas celulares y nuevos procesos. Se trata as\u00ed de medicamentos similares, pero no exactamente id\u00e9nticos, a los productos de referencia, hasta hace poco se les llamaba tambi\u00e9n el t\u00e9rmino biogen\u00e9ricos por analog\u00eda con los f\u00e1rmacos gen\u00e9ricos de s\u00edntesis tradicionales.<\/p>\n<p>Fuente: Medicamentos y farmacia Canal Salut, Generalitat.<\/div>\n<p><strong>Pero uno<\/strong><strong>n medicamento biosimilar no es un medicamento gen\u00e9rico,\u00a0<\/strong>ya que los medicamentos biol\u00f3gicos, como es el caso de las insulinas, est\u00e1n\u00a0<strong>producidos por organismos vivos manipulados gen\u00e9ticamente,\u00a0<\/strong>\u00a0lo que les distingue de los medicamentos de s\u00edntesis qu\u00edmica. Son mol\u00e9culas de estructura compleja y grandes, y en este caso, sus biosimilares no son una copia calcada de la mol\u00e9cula original sino estructuras funcionalmente bioequivalentes, que han demostrado que las leves diferencias estructurales existentes entre ambos productos inherentes a la condici\u00f3n de biol\u00f3gico , no significa cambios en su comportamiento farmacocin\u00e9tico, ni farmacodin\u00e1mico y por tanto que ofrece las mismas garant\u00edas terap\u00e9uticas.<\/p>\n<figure id=\"attachment_21405\" aria-describedby=\"caption-attachment-21405\" style=\"width: 298px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-4.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-21405\" alt=\"biosimilars-COFB-mar\u00e7-2016 (4)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2016\/05\/biosimilars-COFB-mar\u00e7-2016-4.jpg\" width=\"298\" height=\"199\" \/><\/a><figcaption id=\"caption-attachment-21405\" class=\"wp-caption-text\">Mercedes Barau (COFB)<\/figcaption><\/figure>\n<div class=\"box shadow\">\u201cEn principio los biosimilares, a diferencia de los gen\u00e9ricos, <strong>no ser\u00e1n intercambiables ni podr\u00e1n sustituirse las prescripciones<\/strong>, aunque el m\u00e9dico s\u00ed podr\u00e1 adecuar la prescripci\u00f3n de medicamentos, como la insulina o la hormona de crecimiento, por su biosimilar\u201d explica <b>Merc\u00e8 Barau, vocal de la Junta de Gobierno del COFB y coordinadora<\/b> del acto. \u201cCon la experiencia que tenemos en Europa, parece que determinadas mol\u00e9culas como es el caso de la insulina, su biosimilar podr\u00e1n autorizarse con los estudios de farmacocin\u00e9tica y farmacodin\u00e1mica, ya que los estudios de eficiencia y seguridad ya se han hecho con la mol\u00e9cula original\u201d. Y matiza: \u201cen la conferencia tambi\u00e9n se coment\u00f3 que en las distintas comunidades aut\u00f3nomas<strong> no se cambiar\u00e1n tratamientos pero cuando se tengan que empezar de nuevos se empezar\u00e1 el biosimilar<\/strong>\u201d.<\/div>\n<p><b>M\u00e1s informaci\u00f3n:<\/b><\/p>\n<p><a href=\"http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/Medicine_QA\/2009\/12\/WC500020062.pdf\" target=\"_blank\" rel=\"noopener\">Preguntas y respuestas sobre medicamentos biosimilares (medicamentos biol\u00f3gicos similares) (v\u00eda EMA \u2013 European Medicines Agency)<\/a><\/p>\n<p><a href=\"http:\/\/medicaments.gencat.cat\/ca\/professionals\/cedimcat\/documents-divulgatius-del-cedimcat\/medicaments-biotecnologics-i-biosimilars\/#FW_bloc_0b14e4a4-f7b0-11e3-8142-000c290c5684_3\" target=\"_blank\" rel=\"noopener\">Medicamentos biotecnol\u00f3gicos y biosimilares (v\u00eda Canal Salud \u2013 Medicamentos y Farmacia, Gencat)<\/a><\/p>\n<p align=\"right\"><b>Con la colaboraci\u00f3n de: <\/b><\/p>\n<p align=\"right\">\u00a0<a href=\"http:\/\/www.lilly.es\/es\/index.aspx\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11093 alignright\" alt=\"lilly\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/01\/lilly.jpg\" width=\"117\" height=\"68\" \/><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>A finales de 2015 se comercializ\u00f3 en Espa\u00f1a la primera insulina biosimilar de dispensaci\u00f3n en la farmacia comunitaria, la insulina glargina Abasaglar, nombre comercial de la nueva opci\u00f3n de tratamiento para los pacientes con diabetes tipo 1 y 2. Fabricada por los laboratorios Lilly y Boehringer Ingelheim , ha sido lanzada [\u2026]<\/p>","protected":false},"author":1,"featured_media":21404,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[64,2395,2396,2397,45],"class_list":["post-21391","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-atencio-farmaceutica","tag-biosimilar","tag-biosimilars","tag-insulina","tag-medicaments"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber? - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"A finals del 2015 es va comercialitzar a Espanya la primera insulina biosimilar de dispensaci\u00f3 a la farm\u00e0cia comunit\u00e0ria, la insulina glargina Abasaglar, nom comercial de la nova opci\u00f3 de tractament per als pacients amb diabetis tipus 1 i 2. Fabricada pels laboratoris Lilly i Boehringer Ingelheim, ha estat llen\u00e7ada [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-05-18T10:44:09+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber?\",\"datePublished\":\"2016-05-18T10:44:09+00:00\",\"dateModified\":\"2016-05-18T10:44:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\"},\"wordCount\":614,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"Atenci\u00f3 farmac\u00e8utica\",\"biosimilar\",\"biosimilars\",\"insulina\",\"medicaments\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\",\"name\":\"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2016-05-18T10:44:09+00:00\",\"dateModified\":\"2016-05-18T10:44:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/","og_locale":"es_ES","og_type":"article","og_title":"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"A finals del 2015 es va comercialitzar a Espanya la primera insulina biosimilar de dispensaci\u00f3 a la farm\u00e0cia comunit\u00e0ria, la insulina glargina Abasaglar, nom comercial de la nova opci\u00f3 de tractament per als pacients amb diabetis tipus 1 i 2. Fabricada pels laboratoris Lilly i Boehringer Ingelheim, ha estat llen\u00e7ada [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2016-05-18T10:44:09+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber?","datePublished":"2016-05-18T10:44:09+00:00","dateModified":"2016-05-18T10:44:09+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/"},"wordCount":614,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage"},"thumbnailUrl":"","keywords":["Atenci\u00f3 farmac\u00e8utica","biosimilar","biosimilars","insulina","medicaments"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/","url":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/","name":"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage"},"thumbnailUrl":"","datePublished":"2016-05-18T10:44:09+00:00","dateModified":"2016-05-18T10:44:09+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2016\/05\/18\/els-biosimilars-arriben-a-la-farmacia-que-hem-de-saber\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Els biosimilars arriben a la farm\u00e0cia, qu\u00e8 hem de saber?"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"A finals del 2015 es va comercialitzar a Espanya la primera insulina biosimilar de dispensaci\u00f3 a la farm\u00e0cia comunit\u00e0ria, la insulina glargina Abasaglar, nom comercial de la nova opci\u00f3 de tractament per als pacients amb diabetis tipus 1 i 2. Fabricada pels laboratoris Lilly i Boehringer Ingelheim, ha estat llen\u00e7ada [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/21391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=21391"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/21391\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=21391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=21391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=21391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}